Table 2.

Odds ratio (OR) and 95% confidence interval (CI) for pathologic complete response in 369 patients with available sTILs

	Univariable analysis			Multivariable analysis
	OR	95% CI	P		adjusted OR	95% CI	P
Age
≤ 50	Ref.				Ref.
> 50	0.69	0.46–1.04	0.079		0.80	0.51–1.26	0.341
Histologic grade			0.074				0.175
1	Ref.				Ref.
2	3.01	0.33–27.48	0.329		2.17	0.21–22.13	0.512
3	4.55	0.50–41.50	0.179		3.20	0.31–32.78	0.327
Clinical tumor stage			0.126				0.578
1	Ref.				Ref.
2	0.94	0.41–2.13	0.876		0.83	0.35–1.96	0.666
3	0.62	0.25–1.59	0.322		0.67	0.25–1.78	0.417
4	0.25	0.06–1.13	0.071		0.37	0.08–1.81	0.220
Clinical nodal stage							0.555
0	Ref.				Ref.
1	1.15	0.66–2.01	0.612		0.90	0.50–1.64	0.730
2	0.78	0.43–1.40	0.399		0.67	0.35–1.28	0.227
3	0.73	0.30–1.77	0.482		0.64	0.241.72	0.379
sTILs
< 50%	Ref.				Ref.
≥ 50%	1.27	0.79–2.04	0.322		1.60	0.95–2.69	0.079
Regimen							< 0.001
Non-carboplatin	Ref.				Ref.
Carboplatin	2.57	1.58–4.16	< 0.001		2.73	1.64–4.53	< 0.001
Pembrolizumab	3.52	2.02–6.14	< 0.001		4.00	2.20–7.16	< 0.001

sTILs, stromal tumor-infiltrating lymphocytes